Teplizumab Beneficial for Preserving Beta-Cell Function in Pediatric T1D
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
MONDAY, Oct. 23, 2023 -- For children and adolescents with newly diagnosed type 1 diabetes, two 12-day courses of teplizumab show benefit for preservation of beta (β)-cell function, according to a study published online Oct. 18 in the New England Journal of Medicine. The research was published to coincide with the annual meeting of the International Society for Pediatric and Adolescent Diabetes, held from Oct. 18 to 21 in Rotterdam, Netherlands.
Eleanor L. Ramos, M.D., from Provention Bio in Red Bank, New Jersey, and colleagues conducted a randomized, placebo-controlled trial to examine β-cell preservation, clinical end points, and safety in children and adolescents (aged 8 to 17 years) who were randomly assigned to receive two 12-day courses of teplizumab or placebo (217 and 111 patients, respectively).
The researchers found that at week 78, patients treated with teplizumab had significantly higher stimulated C-peptide levels than those receiving placebo (least-squares mean difference, 0.13 pmol/mL). Furthermore, 94.9 and 79.2 percent of patients treated with teplizumab and placebo, respectively, maintained a clinically meaningful peak C-peptide level of 0.2 pmol/mL or greater. With respect to key secondary end points, there was no significant difference observed between the groups. Adverse events, including headache, gastrointestinal symptoms, rash, lymphopenia, and mild cytokine release syndrome, occurred primarily in association with the administration of teplizumab or placebo.
"The present trial showed that two 12-day courses of intravenous teplizumab significantly improved stimulated C-peptide levels, as compared with placebo, at week 78 in patients with stage 3 type 1 diabetes who had enrolled in the trial within six weeks after diagnosis," the authors write.
Several authors disclosed ties to biopharmaceutical companies, including Provention Bio, a Sanofi company, which manufactures teplizumab and funded the study.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted October 2023
Read this next
Men Face More Diabetes Complications Than Women
FRIDAY, May 17, 2024 -- Men with diabetes have a greater risk for complications than women, irrespective of diabetes duration, according to a study published online May 16 in...
Diabetes Increases Risk for Functional Limitations in Older Adults
FRIDAY, May 3, 2024 -- Older adults with diabetes are more likely to develop functional limitations than adults without diabetes, according to a study published online April 16 in...
Prevalence of Type 1 Diabetes Steady in Youth, Adults
WEDNESDAY, April 10, 2024 -- Nearly four in every 1,000 U.S. youths and five in every 1,000 U.S. adults reported having type 1 diabetes from 2019 through 2022, according to a...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.